Amado Patrícia S M, Woodley Christopher, Cristiano Maria L S, O'Neill Paul M
Center of Marine Sciences - CCMAR, University of Algarve, P-8005-039 Faro, Portugal.
Department of Chemistry and Pharmacy, FCT, University of Algarve, P-8005-039 Faro, Portugal.
ACS Omega. 2022 Nov 3;7(45):40659-40681. doi: 10.1021/acsomega.2c05307. eCollection 2022 Nov 15.
Decaprenylphosphoryl-β-d-ribose 2'-epimerase (DprE1) is a critical flavoenzyme in , catalyzing a vital step in the production of lipoarabinomannan and arabinogalactan, both of which are essential for cell wall biosynthesis. Due to its periplasmic localization, DprE1 is a susceptible target, and several compounds with diverse scaffolds have been discovered that inhibit this enzyme, covalently or noncovalently. We evaluated a total of ∼1519 DprE1 inhibitors disclosed in the literature from 2009 to April 2022 by performing an in-depth analysis of physicochemical descriptors and absorption, distribution, metabolism, excretion, and toxicity (ADMET), to gain new insights into these properties in DprE1 inhibitors. Several molecular properties that should facilitate the design and optimization of future DprE1 inhibitors are described, allowing for the development of improved analogues targeting .
Drug Discov Today. 2024-6
Molecules. 2018-2-27
J Biomol Struct Dyn. 2024-8
J Comput Aided Mol Des. 2025-7-9
Front Med (Lausanne). 2024-10-21
ACS Infect Dis. 2024-10-11
Pharmaceuticals (Basel). 2024-5-9
ACS Med Chem Lett. 2022-3-10
Int J Mol Sci. 2022-1-11